MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma

Antonio Facciorusso, Raffaele Licinio, Brian I. Carr, Alfredo Di Leo, Michele Barone

Research output: Contribution to journalArticlepeer-review


Sorafenib is the only approved systemic treatment for advanced hepatocellular carcinoma patients and all the recently published randomized controlled trials on new systemic drugs have been unsuccessful. This is likely due to a lack of understanding of tumor progression, molecular drivers, and liver toxicity, as well as flaws in trial design. An important signaling pathway in hepatocarcinogenesis is the MEK cascade involved in various cellular responses, including adaptation and survival. A key role in this cascade is played by MEK, of which MEK 1/2 represent the prototypes and an interesting target for new oncological drugs. This review analyzes recent developments and future perspectives on the role of MEK inhibitors in hepatocellular carcinoma treatment.

Original languageEnglish
Pages (from-to)993-1003
Number of pages11
JournalExpert Review of Gastroenterology and Hepatology
Issue number7
Publication statusPublished - Sep 1 2015


  • HCC
  • liver cancer
  • MEK
  • refametinib
  • sorafenib

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this